Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 May 2024
State of the Nation Book Launch

The Vice-Chancellor and Principal, Prof Francis Petersen, invites you to attend the upcoming book launch of State of the Nation: Quality of Life and Wellbeing.

Celebrating its 20th year of existence, this HSRC flagship publication serves as an invaluable, independent scholarly resource offering insights into the current state of South Africa. The theme of the 2024 edition, Quality of Life and Wellbeing, underscores the commitment to understanding and addressing critical societal issues. Edited by Profs Vasu Reddy, Narnia Bohler-Muller, Zitha Mokomane, and Crain Soudien, this edition builds on the preceding editions, focusing on HSRC priorities of poverty and inequality in novel and relevant ways.

During the launch, UFS scholars and editors will hold an interactive session and panel discussion; we look forward to your participation, which will help to enrich the conversations.

 

Date: Thursday 13 June 2024

Time:  15:00 to 16:30 (guests required to be seated by 14:45)

Venue: Equitas Auditorium, Bloemfontein Campus

RSVP:   https://ufsweb.co/3QGWpXY  before 10 June 2024

Contact: For more information, please contact Pienaaran1@ufs.ac.za

ONLY MS Teams for Qwaqwa and South Campus staff (upon request to the RSVP address)

Books available for purchase at the event venue. Card payments will only be accepted.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept